Signal Genetics, Inc. (NASDAQ:SGNL)’s shares skyrocketed 126.65% and led the share to trade at $3.99, depicting no news regarding the unusual surge of the company. Signal Genetics, Inc. (NASDAQ:SGNL)’s stock volatility for the week is 9.48%, while for the month remained 11.46%. With recent incline, the year-to-date (YTD) performance reflected a -30.71% decline. During the past month the stock lost -41.53%, bringing three-month performance to -43.41% and six-month performance to -62.95%.
Signal Genetics, Inc. (NASDAQ:SGNL), formerly on February 2, declared the U.S. Federal Drug Administration (FDA) conditionally approved its proprietary prognostic genetic test, MyPRS (Myeloma Prognostic Risk Signature(R)), for use as entry criteria for an forthcoming clinical trial to treat high-risk multiple myeloma (MM) patients sponsored by the University of Arkansas for Medical Sciences (UAMS).
Signal Genetics, Inc. (NASDAQ:SGNL), headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that assist physicians make better-informed decisions concerning the care of their patients suffering from cancer.
Cytokinetics, Incorporated (NASDAQ:CYTK), inclined 17.89% to close at $7.65, soon after the news release that Cytokinetics, Incorporated (NASDAQ:CYTK), stated total research and development proceeds for the fourth quarter of 2014 were $21.8 million, contrast to $24.3 million during the same period in 2013. The net revenue for the fourth quarter was $8.4 million, or $0.23 per basic and diluted share. This is contrast to a net revenue for the same period in 2013, of $6.5 million, or $0.22 per basic share and $0.21 per diluted share. As of December 31, 2014, cash, cash equivalents and investments totaled $83.2 million, which comprises the receipt of $10 million for the sale of ordinary stock to Astellas Pharma Inc., but does not comprise $45.0 million received from Astellas in January 2015. With the recognition of a milestone payment under its partnership contract with Astellas, the company exceeded its 2014 financial guidance.
Cytokinetics, Incorporated (NASDAQ:CYTK), is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
Biocept, Inc. (NASDAQ:BIOC), surged 11.76% and is now trading at $1.33, after Biocept, Inc. (NASDAQ:BIOC), declared the pricing of an underwritten public offering of 8,000,000 shares of its ordinary stock and warrants to purchase up to an aggregate of 8,000,000 shares of its ordinary stock at a combined offering price of $1.25. The warrants will have a per share exercise price of $1.56, are exercisable right away and will expire five years from the date of issuance. The gross proceeds to Biocept from this offering are predictable to be about $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Biocept has granted the underwriters a 45-day option to purchase up to an additional 1,200,000 shares of ordinary stock and/or 1,200,000 additional warrants to cover over-allotments, if any. The offering is predictable to close on February 13, 2015, subject to customary closing conditions. Aegis Capital Corp. and Feltl and Company, Inc. are acting as joint book-running managers for the offering.
Biocept, Inc. (NASDAQ:BIOC), headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients’ tumors to physicians using its proprietary technology platform to assist improve individual patient treatment.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), gained 5.51% & is now at $7.28.
In press release of February 11, Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), declared that it will present at the RBC Capital Markets’ Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Wednesday, February 25, at 8:00 a.m. (ET).
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines.
